Can a Hybrid Aspirin Daily Prevent Cancer?

A new research study published in the journal ACS Medicinal Chemistry Letters and another to appear in journal Biochemical and Biophysical Research Communication that is now available online concluded that scientists have developed a hybrid aspirin that is safer than the old aspirin and curbs the growth of 11 different types of human cancer cells in culture without harming normal cells. Cancers controlled included colon, pancreatic, lung, prostate, breast, and leukemia. In the other study the compound shrank human colon cancer tumors by 85 percent in live animals without adverse effects. The researchers said “the key component of the new compound  are that they are very, very potent and yet it has minimal toxicity to the cells. ”

The problem with regular aspirin has been  that prolonged use causes side effects ranging from bleeding ulcers to kidney failure.  Building on regular aspirins  researchers have added two molecules that have been shown to increase the drugs safety and called the compound NOSH-aspirin. One arm of the hybrid aspirin releases nitric oxide that helps protect the stomach lining and the other releases hydrogen sulfide that enhances its cancer fighting properties. The aspirin is more potent and 24 hours after treating a culture of cancer cells the NOSH aspirin demonstrated 100,000 times greater potency than aspirin alone. At 72 hours it was about 250,000 times greater in potency in in-vitro cell cultures against human colon cancer. The researchers say this means a lower dose would be required to be effective and would minimize or eliminate side effects.  In the second study, NOSH aspirin was given to mice bearing human colon cancer tumors and the compound caused the cancer cells to self destruct, inhibited proliferation of the cells, and reduced tumor growth without signs of toxicity in the mice.  Further testing of toxicity and clinical trials are planned as a next step.

Tags: , ,

Comments are closed.